Roussel Uclaf

About: Roussel Uclaf is a based out in . It is known for research contribution in the topics: Alkyl & Alkoxy group. The organization has 1888 authors who have published 2338 publications receiving 36508 citations.

Steroid products carrying a substituted thioethyl group in position 10, a process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them

Abstract: Products of formula (I): … … in which:… R = H, alkyl, alkenyl, alkynyl, haloalkyl or alkylthio, (-> 6c) or arylthio, aryl, acyl (-> 12c) or CN (CH2)m-Rc in which Rc denotes OH, SH or Salk (1 to 6c), cycloalk (3 to 6c), m = 1, 2 or 3, X = O N-OR1, R1 = H, alk or … … (-> 10c), Z = H; alk (-> 10c), n = 0, 1 or 2, the dotted lines denote the optional presence of a second bond, process for their preparation and the intermediates of this process, their application as medications and the pharmaceutical compositions containing them.

Process for the preparation of ursodeoxycholic acid starting from 3-alpha, 7-beta, 12-alpha-trihydroxy cholanic acid, and intermediates used

Abstract: 1. Claims (for the Contracting States : AT, BE, CH, DE, GB, LI, NL) Preparation process of ursodesoxycholic acid with the formula I see diagramm : EP0072293,P9,F2 characterized in that 3 alpha, 7 beta, 12 alpha-trihydroxycholanic acid with the formula II see diagramm : EP0072293,P9,F3 is treated with a reactional derivative of an organic radical with the formula R-CO- in which R represents a hydrogen atom or an alkyl or alkoxy radical having from 1 to 5 carbon atoms or an alkenyloxy radical having from 2 to 5 carbon atoms, a cycloalkyloxy radical having from 3 to 7 carbon atoms or an aralkyloxy radical having from 7 to 12 carbon atoms, an aryl or aralkyl radical having from 6 to 12 carbon atoms, each of these radicals possibly carrying one or more substituents, so as to obtain a product with the formula III : see diagramm : EP0072293,P9,F4 which product with the formula III is treated with bromine in a basic medium so as to obtain a product with the formula IV see diagramm : EP0072293,P9,F5 which product with the formula IV is saponified so as to obtain a product with the formula V : see diagramm : EP0072293,P10,F1 or a salt of this product, which product with the formula V or which salt is treated with hydrazine in the presence of diethylene glycol and a base so as to obtain the sought ursodesoxycholic acid. 1. Claims (for the Contracting State IT) Preparation process of ursodesoxycholic acid with the formula I see diagramm : EP0072293,P10,F2 characterized in that 3 alpha, 7 beta, 12 alpha-trihydroxycholanic acid with the formula II see diagramm : EP0072293,P10,F3 is treated with a reactional derivative of an organic radical with the formula R-CO- in which R represents a hydrogen atom or an alkyl or alkoxy radical having from 1 to 5 carbon atoms or an alkenyloxy radical having from 2 to 5 carbon atoms, a cycloalkyloxy radical having from 3 to 7 carbon atoms or an aralkyloxy radical having from 7 to 12 carbon atoms, an aryl or aralkyl radical having from 6 to 12 carbon atoms, each of these radicals possibly carrying one or more substituents, so as to obtain a product with the formula III : see diagramm : EP0072293,P11,F1 which product with the formula III is treated with an oxidizing agent so as to obtain a product with the formula IV see diagramm : EP0072293,P11,F2 which product with the formula IV is saponified so as to obtain a product with the formula V : see diagramm : EP0072293,P11,F3 or a salt of this product, which product with the formula V or which salt is treated with a reducing agent so as to obtain the sought ursodesoxycholic acid.

Cephalosporanic acid derivatives

Abstract: Novel syn isomers of 7-amino-thiazolyl-acetamido-3-acetoxymethyl-cephalosporanic acid derivatives of the formula ##STR1## wherein R 1 is selected from the group consisting of --CN, --CONH 2 and --COOR 1 ', R 1 ' is selected from the group consisting of alkyl of 1 to 3 carbon atoms, hydrogen, alkali metal, alkaline earth metal, ammonium, magnesium and a non-toxic, pharmaceutically acceptable organic amine, A is selected from the group consisting of hydrogen, alkali metal, alkaline earth metal, ammonium, magnesium and a non-toxic, pharmaceutically acceptable organic amine, R' and R" are individually selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms with the ##STR2## group in the syn position with the proviso that when R 1 is --COOR 1 ' and R 1 ' is hydrogen, A is hydrogen and when R 1 is --COOR 1 ' and R 1 ' is an alkali metal, alkaline earth metal, magnesium, ammonium or an organic amine, A is an alkali metal, alkaline earth metal, magnesium ammonium or an organic amine having antibiotic properties and novel intermediates and processes.

Antitumoral composition based on polypeptides having human interleukin 2 activity

Abstract: The use of a polypeptide having human interleukin 2 activity for preparing a pharmaceutical composition for treating malignant epithelial tumours of the upper respiratory/alimentary tract or the thymus, is described.